Using FH-deficient tumors derived from HLRCC patients and sporadic leiomyomas with biallelic loss of FH, we recently showed that AKR1B10 immunohistochemistry can act as a biomarker on protein-level as well [17]. Here, FH is linked to hereditary leiomyomatosis and renal cell cancer.